FDA grants fast track designation to glutaminase inhibitor CB-839 in combination with cabozantinib for metastatic kidney cancer

Calithera Biosciences announced earlier this week that the US Food and Drug Administration (FDA) has granted fast track designation to CB-839 for use in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of treatment (including at least one TKI). Fast track designation by the FDA […]

read more

New ‘fast track’ plans will help to bring promising drugs to the NHS up to 4 years sooner

The Telegraph has reported on comments made by Jeremy Hunt MP, Secretary of State for Health, about plans to help bring promising drugs and medical innovations to the NHS sooner. Mr Hunt discussed plans to ‘fast track’ approval of treatments identified by experts as having the greatest potential to change lives. The Accelerated Access Pathway (AAP) […]

read more
Showing all 2 results